Espero Pharmaceuticals and Armetheon to merge and create a premier cardiovascular focused biopharmaceutical company.
Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing novel drugs addressing unmet needs in cardiovascular diseases, announced their plans to merge. Upon completion of the merger, which is expected to occur in the second quarter of 2017, the combined company will be named Espero BioPharma, Inc.
The merger will create a cardiovascular biopharmaceutical company with a portfolio of recent FDA-approved products, a robust late-stage pipeline, and a growth plan focused on developing products, acquisitions and the commercialization of portfolio products in the U.S. and with partners worldwide.
Armetheon recently announced it has reached agreement with the U.S. Food and Drug Administration (FDA) for a single 1,000 patient final pivotal trial for its leading drug candidate, tecarfarin (Tecarfarin for AntiCoagulation Trial or TACT) prior to filing a New Drug Application (NDA), which is currently projected to occur in 2019.
Tecarfarin is positioned to potentially be, if approved, the oral anticoagulant (OAC) therapy of choice for patients who require anticoagulation with a Vitamin K antagonist (VKA), such as warfarin.
There are at least 15 conditions requiring OAC therapy where a VKA such as warfarin is predominantly used because of a need for a strong anticoagulant, contraindications, or recommended by professional medical societies. These conditions represent at least 1.7 million patients in the U.S. alone, with 91% of these patients taking at least one cytochrome P450 (CYP) interacting drug.
“Armetheon’s promising late stage pipeline and Espero’s leadership and commercialization expertise will result in a biopharmaceutical company solely focused on commercializing standard of care medicines as well as developing and approving late stage candidates treating cardiovascular diseases.” commented Peter Milner, M.D. FACC, Co-Founder and Executive Chairman of Armetheon.
Espero’s currently marketed products include GoNitroTM (nitroglycerin) sublingual powder for the acute relief and prophylaxis of angina pectoris, which recently was awarded recognition by the Journal of Emergency Medical Services. Leveraging its existing and scalable commercial platform, Espero has the ability to commercialize tecarfarin and potential new product acquisitions.
“Cardiovascular diseases are the number one cause of death in the U.S. and worldwide, yet less than 10 percent of the new chemical entities approved by FDA in the last six years are for the treatment of cardiovascular diseases. Espero is committed to bringing new treatment options to patients in this underinvested therapeutic category, while also delivering significant benefits to all our stakeholders,” said Quang Pham, founder, Chairman and Chief Executive Officer of Espero, who was selected by both boards of directors to lead the combined company.
(Source: Business Wire)